.

ISSN 2063-5346
For urgent queries please contact : +918130348310

A CASE REPORT ON FENOFIBRATE AND ATORVASTATIN INDUCED – RHABDOMYOLYSIS

Main Article Content

P. Divya Bhargavi, Bhukya Vijay Nayak , Basavan Duraiswamy, Reshma Ajay, Challa Srilekha , Vinyas Mayasa , Siddhartha Lolla
» doi: 10.31838/ecb/2023.12.si5.076

Abstract

Background: Here we report a unique case study to report evidence of rhabdomyolysis caused by the interaction of fenofibrate and atorvastatin and to learn about a suitable alternative medication. Methods: Case study as well as a review of the relevant literature. Findings: A female patient of age 55 years was admitted to the hospital with complaints of cough, breathlessness, mild expectorate, fever, and pain near the chest for three days and a history of weakness. The patient has a past medical history of hypertension [treated with amlodipine] and diabetes mellitus [treated with tab glimepiride 2mg + metformin 500mg]. The patient’s lab investigations showed decreased haemoglobin level [8.2gm/dl], packed cell volume [20.6], mean corpuscular volume [73.1], mean corpuscular haemoglobin [25.6], red blood cell [2.5mill/cumm] decreased count. Implications: The patient had taken Fenofibrate and Atorvastatin, which will enhance the effects of one another through pharmacodynamic synergism. When combined with an optimal statin regimen to lower triglycerides and increase high-density lipoproteins, fenofibrate may increase the risk of rhabdomyolysis. Hence has to be monitored proportionately. As an alternative to Fenofibrate, Ezetimibe was given which resulted in no interactions that were previously seen and reported.

Article Details